| abstract |
A novel therapeutic composition and methods for using it in anti-angiogenic and anti-tumor treatments. The composition comprises a biologically effective amount of an anti-VEGF antibody, or antigen-binding fragment thereof, that binds to substantially the same epitope as the monoclonal antibody ATCC PTA 1595 and that binds to the VEGF receptor VEGFR1. Significantly inhibits VEGF binding to the VEGF receptor VEGFR2 (KDR / Flk-1) without significantly inhibiting VEGF binding to (Flt-1). [Selection] Figure 4 |